Los Angeles, CA -- (SBWIRE) -- 05/20/2019 -- This study researches the market size of Drugs for Vulvovaginal Candidiasis, presents the global Drugs for Vulvovaginal Candidiasis sales and revenue by companies, regions, type and application, history breakdown data from 2013 to 2018, and forecast to 2025.
This report focuses on the key data information of Drugs for Vulvovaginal Candidiasis in key regions like North America, Europe, Asia Pacific, Central & South America, and Middle East & Africa, presents sales, revenue, market share, growth rate of Drugs for Vulvovaginal Candidiasis for each region and countries in each region.
For top companies, this report investigates and analyzes the sales, revenue, market share and growth rate for the top players, key data from 2013 to 2018.
This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.
Get PDF template of this report: https://www.qyresearch.com/sample-form/form/720109/global-drugs-for-vulvovaginal-candidiasis-industry-research-report-growth-trends-and-competitive-analysis-
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%.
The drugs for Vulvovaginal Candidiasis are Miconazole, Clotrimazole, Fluconazole, Econazole and Other, market share of Fluconazole is about 24.5% in 2017.
Drugs for Vulvovaginal Candidiasis is application in Hospital & Clinic and Pharmacy. The most of Drugs for Vulvovaginal Candidiasis is used in Pharmacy, and the market share in 2016 is about 59%.
In 2018, the global Drugs for Vulvovaginal Candidiasis market size was 770 million US$ and is forecast to 860 million US in 2025, growing at a CAGR of 1.5% from 2018. In this study, 2017 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Drugs for Vulvovaginal Candidiasis.
This report includes the following manufacturers; we can also add the other companies as you want.
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Market Segment by Product Type
Cream
Pessary
Other
Market Segment by Application
Hospital & Clinic
Pharmacy
Market size split by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Egypt
South Africa
Get Full Report Now at USD 3,550 @ https://www.qyresearch.com/settlement/pre/444f694cf0b065bd9763d524c353e2f1,0,1,Global%20Drugs%20for%20Vulvovaginal%20Candidiasis%20Industry%20Research%20Report,%20Growth%20Trends%20and%20Competitive%20Analysis%202018-2025
About QYResearch
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in the consulting industry.